<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088217</url>
  </required_header>
  <id_info>
    <org_study_id>2R01HL097163</org_study_id>
    <nct_id>NCT01088217</nct_id>
  </id_info>
  <brief_title>Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
  <acronym>GWAS</acronym>
  <official_title>Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Landspitali University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate inherited genetic factors that play a role in the
      development of familial pulmonary fibrosis and to identify a group of genes that predispose
      individuals to develop pulmonary fibrosis. Finding the genes that cause pulmonary fibrosis is
      the first step at developing better methods for early diagnosis and improved treatment for
      pulmonary fibrosis. The overall hypothesis is that inherited genetic factors predispose
      individuals to develop pulmonary fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Familial Pulmonary Fibrosis (FPF) is a sub-category of the idiopathic interstitial pneumonias
      (IIPs). IIPs are progressive lung conditions, with limited treatment options and unknown
      etiology. Though the IIPs have been associated with both genetic risk factors and
      environmental exposures, the molecular mechanism underlying disease progression remain poorly
      understood. This investigation seeks to identify a group of genetic loci that play a role in
      the development of familial interstitial pneumonia (FIP) or FPF, where 2 or more cases of IIP
      are seen within a family.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify a group of genetic loci that play a role in the development of familial interstitial pneumonia and idiopathic interstitial pneumonia.</measure>
    <time_frame>10 years</time_frame>
    <description>The purpose of this study is to investigate inherited genetic factors that play a role in the development of pulmonary fibrosis and to identify a group of genetic loci/genes that predispose individuals to develop IIP. We will achieve this goal by employing various methods of genetic technology for gene discovery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Develop biomarkers using proteomic and genomic approaches that will facilitate establishing the diagnosis and prognosis of both familial and sporadic forms of idiopathic interstitial pneumonia (IIP).</measure>
    <time_frame>10 years</time_frame>
    <description>A peripheral blood biomarker or biological signature (gene or protein expression pattern) of idiopathic interstitial pneumonias (IIPs) will simplify and improve the accuracy of diagnosis of IIP and diagnose individuals at an earlier, more treatable, stage of their disease. A peripheral blood biomarker for the diagnosis of IIPs and other interstitial lung diseases (ILDs) will potentially decrease the need for invasive surgical lung biopsy, and thereby avoid the additional cost, morbidity, and mortality associated with surgical lung biopsy.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <condition>Familial Pulmonary Fibrosis</condition>
  <condition>Idiopathic Interstitial Pneumonia</condition>
  <condition>Familial Interstitial Pneumonia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, plasma, lung tissue, DNA, RNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Families with two or more individuals diagnosed with Idiopathic Pulmonary Fibrosis (IPF) or
        Idiopathic Interstitial Pneumonia (IIP)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Two or more family members with a clinical diagnosis of Idiopathic Pulmonary Fibrosis
             (IPF) or Idiopathic Interstitial Pneumonia (IIP)

          -  Additional family members may be eligible to participate if two family members are
             suspected of or diagnosed as having Idiopathic Pulmonary Fibrosis (IPF) or Idiopathic
             Interstitial Pneumonia (IIP)

        Exclusion Criteria:

          -  Individuals whose pulmonary fibrosis is due to a known cause rather than idiopathic

          -  Individuals whose pulmonary fibrosis is due to a broader genetic syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A. Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Denver; National Jewish Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Powers, MHS</last_name>
    <phone>303-724-6539</phone>
    <email>julia.powers@ucdenver.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janet Talbert, MS, CGC</last_name>
    <phone>1-800-423-8891</phone>
    <phone_ext>1022</phone_ext>
    <email>talbertj@njhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Powers, MHS</last_name>
      <phone>303-724-6539</phone>
      <email>julia.powers@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janet Talbert, MS, CGC</last_name>
      <phone>1-800-423-8891</phone>
      <phone_ext>1022</phone_ext>
      <email>talbertj@njhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>David A. Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marvin I Schwarz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivana Yang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tasha E Fingerlin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Keith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlyne Cool, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Peljto, DrPh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Jewish Health and University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Talbert, MS, CGC</last_name>
      <phone>800-423-8891</phone>
      <phone_ext>1022</phone_ext>
      <email>talbertj@njhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Julie Powers, MHS</last_name>
      <phone>303-724-6539</phone>
      <email>julia.powers@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David A. Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin K. Brown, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory P. Cosgrove, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marvin I. Schwarz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tasha Fingerlin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steve Groshong, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Lynch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Crapo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Markin, MT</last_name>
      <phone>888-898-1550</phone>
      <email>cheryl.markin@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>James E. Loyd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Landspitali University Hospital</name>
      <address>
        <city>Reykjavik</city>
        <country>Iceland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gunnar Gudmundsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iceland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Pulmonary Fibrosis</keyword>
  <keyword>Familial Pulmonary Fibrosis</keyword>
  <keyword>Idiopathic Interstitial Pneumonia</keyword>
  <keyword>Familial Interstitial Pneumonia</keyword>
  <keyword>Pulmonary Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

